Mode
Text Size
Log in / Sign up
N/A N=10 Device Feasibility

Evaluation of Sound Processor for a Transcutaneous System

Conductive Hearing Loss · Mixed Hearing Loss

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Aided Thresholds Fusion-unaided PTA — 29.6 dB

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fusion Sound Processor (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Oticon Medical
Primary completion
Nov 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Aided Thresholds Fusion-unaided PTA
29.6
SECONDARY
Aided Thresholds Fusion-unaided
10.05; 26.5; 36.5; 38.0; 28.5; 27.5
SECONDARY
Aided Thresholds Fusion PTA4
-0.290; -1.07; -0.78
SECONDARY
Aided Thresholds Fusion
SECONDARY
Aided Thresholds Fusion-BCI PTA4
SECONDARY
Aided Thresholds Fusion-BCI
SECONDARY
Speech Intelligibility Fusion-unaided %
SECONDARY
Speech Intelligibility Fusion-unaided Signal to Noise Ratio (SNR)
SECONDARY
Speech Intelligibility Fusion %
SECONDARY
Speech Intelligibility Fusion SNR
SECONDARY
Speech Intelligibility Fusion-BCI %
SECONDARY
Speech Intelligibility Fusion-BCI SNR
SECONDARY
Magnet Strength
SECONDARY
IPS (Inflammation, Pain, Skin Height/Numbness) Evaluation
SECONDARY
Subjective Evaluation
SECONDARY
Subjective Evaluation SSQ

Summary

A single center study evaluating the performance of an externally worn sound processor for a transcutaneous bone anchored hearing system using audiological outcomes measures such as aided thresholds and speech intelligibility and self evaluation questionnaires.

Eligibility Criteria

Inclusion Criteria

  • Subjects implanted with the Bridging Bone Conductor (BBC) implant
  • Subjects that have completed one year follow up in Osseofon BCI (Bone Conduction Implant) study
  • Subjects available for 6 months study procedures without affecting the follow ups in the Osseofon BCI study
  • Active user of the BCI SP

Exclusion Criteria

  • Inability to participate in follow-ups
  • Unsuitable as judged by the principle investigator or the sub-investigator
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03374787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search